Reviews

 ASTEC LIFESCIENCES LTD.

Ticker : 533138 
FV : Rs 10 
52-Week H/L : Rs 1,528.00/ 647.05

We had previously recommended Astec LifeSciences in volume 37, no. 14, dated January 25, 2021, when the scrip was trading at Rs 1,263.50 per share. It was recommended based on the company’s new product launches that are auguring well for its growth trend. The company’s consolidated quarterly results of Q4FY21 show that its net sales have decreased by 4.79 per cent to Rs 171.92 crore from Rs 180.57 crore reported in Q4FY20. PBDT came in at Rs 38.70 crore for Q4FY21, contracting by 15.46 per cent as compared to Rs 45.78 crore for Q4FY20. Astec LifeSciences reported a net profit of Rs 23.96 crore in Q4FY21, which is a decline of 23.14 per cent from Rs 31.18 crore posted in Q4FY20. Considering the recent positive momentum seen in the company's stock, we recommended to BOOK PROFIT at Rs 1,475.60 per share as of May 24, 2021, with a gain of 16.78 per cent.